Study guide
7.1 Acute Pulmonary Embolism: Risk Stratification & Thrombolytic Therapy
BCEMP Board Certified Emergency Medicine Pharmacist Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Introduction, Triage, and Resuscitation Fundamentals
1.1 BCEMP Exam Logistics, Content Outlines & Scoring 1.2 Emergency Triage Systems (ESI) & Pre-Hospital Care Coordination 1.3 Resuscitation Pharmacology, Pharmacokinetics & Vascular Access
2 Chapter 2: Cardiac Arrest and Dysrhythmias
2.1 Adult Cardiac Arrest & ACLS Pharmacotherapy Protocols 2.2 Acute Tachyarrhythmias: Narrow- and Wide-Complex Management 2.3 Symptomatic Bradycardia & Vasoactive Chronotropic Support 2.4 Post-Cardiac Arrest Care & Targeted Temperature Management (TTM)
3 Chapter 3: Shock and Hemodynamic Resuscitation
3.1 Sepsis & Septic Shock: Surviving Sepsis Campaign 2026 Resuscitation 3.2 Cardiogenic & Obstructive Shock, Mechanical Circulatory Support & LVADs 3.3 Hypovolemic & Hemorrhagic Shock Fluid Protocols
4 Chapter 4: Airway Management and Rapid Sequence Intubation (RSI)
4.1 Rapid Sequence Intubation (RSI) Process & Pretreatment Agents 4.2 RSI Induction Agents: Pharmacology, Selection & Dosing 4.3 Neuromuscular Blocking Agents & Post-Intubation Analgosedation
5 Chapter 5: Neurocritical Care and Neurologic Emergencies
5.1 Acute Ischemic Stroke: Thrombolysis & Blood Pressure Control 5.2 Intracranial Hemorrhage & Elevated ICP Pharmacotherapy 5.3 Status Epilepticus: Tiered Emergent Anticonvulsant Therapy 5.4 Traumatic Brain Injury & Spinal Cord Emergencies
6 Chapter 6: Acute Coronary Syndromes and Acute Heart Failure
6.1 Acute Coronary Syndromes: STEMI & NSTE-ACS Pharmacotherapy 6.2 Acute Decompensated Heart Failure & Cardiogenic Pulmonary Edema 6.3 Hypertensive Crises: Emergencies, Urgencies & Target Blood Pressure
7 Chapter 7: Pulmonary and Allergic Emergencies
7.1 Acute Pulmonary Embolism: Risk Stratification & Thrombolytic Therapy 7.2 Severe Asthma Exacerbation & COPD Acute Management 7.3 Anaphylaxis & Severe Allergic Reactions: Acute Epinephrine Protocols
8 Chapter 8: Clinical Toxicology: Approach to Poisoning and Common Overdoses
8.1 Approach to the Poisoned Patient: Poison Centers, Toxidromes, Decontamination & Enhanced Elimination 8.2 Acetaminophen Overdose & N-Acetylcysteine Dosing Strategies 8.3 Salicylate Toxicity & Toxic Alcohol Management (Fomepizole) 8.4 Opioid Toxicity & Sedative-Hypnotic/Alcohol Withdrawal Syndromes 8.5 Beta-Blocker & Calcium Channel Blocker Toxicity (HIET, Calcium, Glucagon)
9 Chapter 9: Toxicology: Specialized Poisonings and Antidotes
9.1 Digoxin, Tricyclic Antidepressants & Anticholinergic Toxicity 9.2 Cyanide, Carbon Monoxide & Organophosphate/Cholinergic Toxins 9.3 Snake and Spider Envenomations & Heavy Metal Chelation 9.4 Additional Antidotes: Methemoglobinemia, Isoniazid, Sulfonylureas, Valproate, Sympathomimetics & LAST
10 Chapter 10: Hemostasis, Anticoagulant Reversal, and Hematology
10.1 DOAC & Warfarin Reversal: Specific Reversal Agents & 4F-PCC 10.2 Heparin-Induced Thrombocytopenia (HIT) & Direct Thrombin Inhibitors 10.3 Sickle Cell Vaso-Occlusive Crises & Acute Chest Syndrome
11 Chapter 11: Endocrine, Electrolyte, and Metabolic Emergencies
11.1 Diabetic Ketoacidosis (DKA) & Hyperosmolar Hyperglycemic State (HHS) 11.2 Severe Electrolyte Emergencies: Hyperkalemia & Hyponatremia 11.3 Endocrine Crises: Thyroid Storm, Myxedema Coma & Acute Adrenal Crisis 11.4 Acute Kidney Injury, Dialyzability & Drug Dosing during RRT
12 Chapter 12: Infectious Diseases and Antimicrobial Stewardship
12.1 Severe Community & Hospital-Acquired Infections in the ED 12.2 Skin & Soft Tissue, STI, and Vector-Borne Emergencies 12.3 ED Antimicrobial Stewardship & Rapid Microbiologic Diagnostics
13 Chapter 13: Special Populations: Pediatrics, Trauma, and Obstetrics
13.1 Pediatric Resuscitation, Status Epilepticus & PALS Pharmacotherapy 13.2 Trauma Pharmacotherapy: Massive Transfusion, TXA, Open Fractures, Tetanus & Burns 13.3 Obstetric & Gynecologic Emergencies: Preeclampsia, Eclampsia & PPH
14 Chapter 14: Medication Safety, ED Operations, and Disaster Preparedness
14.1 ED High-Alert Medications, Error Reporting & Technology Safeguards 14.2 ED Workflow, Transitions of Care & Boarding Patient Management 14.3 Mass Casualty Incidents, CBRNE Countermeasures & Strategic Stockpiles
15 Chapter 15: Biostatistics, Study Design, and Literature Evaluation
15.1 Biostatistics & Hypothesis Testing: Power, Errors & Interpretations 15.2 Clinical Study Designs & Measures of Effect 15.3 Literature Evaluation, Clinical Guidelines & Research Conduct in the ED
16 Chapter 16: Medical Devices, Ventilation, and Medication Delivery
16.1 Mechanical Ventilation, Noninvasive Ventilation & High-Flow Oxygen: What the Pharmacist Must Know 16.2 Vascular Access, Enteral Tubes, Drains & Extravasation Management 16.3 Infusion Pumps, Patient-Owned Devices & Medication Delivery Device Counseling
17 Chapter 17: Organ-System Emergencies: GI, GU, Oncology, Neurology, ENT, Pain, and Psychiatry
17.1 Gastrointestinal & Hepatic Emergencies: GI Bleeding, Cirrhosis Complications, Pancreatitis & Vomiting 17.2 Genitourinary Emergencies: UTI & Pyelonephritis, Renal Colic, Urinary Retention, Priapism & Scrotal Infections 17.3 Oncologic, Immunotherapy & Hematologic Emergencies: Febrile Neutropenia, TLS, Hypercalcemia, irAEs, CAR-T, Hemophilia & TTP 17.4 Headache & Neuromuscular Emergencies: Migraine, Cluster, Myasthenic Crisis, Guillain-Barré & Bell's Palsy 17.5 Ophthalmologic, ENT & Dental Emergencies: Eye Injuries, Angle Closure, Angioedema, Epistaxis, Ear & Throat Infections and Dental Pain 17.6 Acute Pain Management & Procedural Sedation and Analgesia in the ED 17.7 Psychiatric Emergencies: Severe Agitation, Serotonin Syndrome, NMS, Lithium Toxicity & Psychotropic Overdose
18 Chapter 18: Special Populations, Medication Access, and Professional Practice
18.1 Pharmacogenomics, Adverse Drug Events & High-Risk Drug Interactions in Emergency Care 18.2 Special Populations: Older Adults, Extremes of Weight, Pregnancy & Lactation, and Immunocompromised Patients 18.3 Social Determinants of Health, Health Literacy & Medication Access at ED Discharge 18.4 Healthcare Regulations & Standards: FDA, REMS, Bar Coding, DEA, CMS, EMTALA, The Joint Commission, NIOSH & USP 18.5 Formulary & Inventory Management, Drug Shortages, Antidote Stocking & Clinical Decision Support 18.6 Quality Improvement, Practice Standards & Interprofessional Collaboration (Protocols, Teamwork & Debriefing)
7.1 Acute Pulmonary Embolism: Risk Stratification & Thrombolytic Therapy
Key Takeaways Explain This Topic AI
Guideline-directed risk stratification (ESC/AHA) categorizes pulmonary embolism into High-Risk (Massive), Intermediate-Risk (Submassive; subdivided into Intermediate-High and Intermediate-Low), and Low-Risk based on hemodynamic stability, right ventricular dysfunction, and cardiac biomarker elevation.
Systemic thrombolysis with alteplase 100 mg IV over 2 hours (or accelerated 50 mg IV push over 15 minutes during cardiac arrest or impending arrest) is indicated for high-risk massive PE presenting with obstructive shock, reducing mortality at the cost of a 1.5% to 2% risk of intracranial hemorrhage.
In intermediate-high risk PE, the landmark PEITHO trial demonstrated that routine systemic thrombolysis reduces hemodynamic decompensation but significantly increases major bleeding and hemorrhagic stroke without reducing overall mortality; routine systemic thrombolysis is therefore withheld in favor of close monitoring and rescue reperfusion.
Catheter-directed thrombolysis (CDT: low-dose alteplase 0.5–1.0 mg/h per catheter over 12–24 hours) and mechanical thrombectomy provide rapid local clot debulking while significantly limiting systemic bleeding in high-bleeding-risk or deteriorating intermediate-risk patients.
Immediate parenteral anticoagulation with unfractionated heparin (80 units/kg bolus, 18 units/kg/h infusion) is preferred in massive PE due to rapid titration and reversal, while direct oral anticoagulants (apixaban 10 mg PO BID x 7 days, rivaroxaban 15 mg PO BID with food x 21 days) serve as first-line monotherapies in hemodynamically stable patients.
Last updated: October 2026
7.1 Acute Pulmonary Embolism: Risk Stratification & Thrombolytic Therapy
Note
Independent BCEMP study resource provided by ExamFinch. Content covers Board of Pharmacy Specialties (BPS) Emergency Medicine Pharmacy examination topics.
Pathophysiology & Hemodynamic Collapse
Acute pulmonary embolism (PE) is an emergent, life-threatening manifestation of venous thromboembolism (VTE). Physical obstruction of the pulmonary arterial bed combined with neurohumoral pulmonary vasoconstriction (mediated by thromboxane A2 and serotonin released from activated platelets) causes an abrupt surge in pulmonary vascular resistance (PVR). Because the thin-walled right ventricle (RV) cannot acutely generate peak systolic pressures exceeding 40 to 50 mmHg, this sudden increase in afterload triggers acute right ventricular dilation, increased RV wall tension, and RV myocyte ischemia. SPIRAL OF RIGHT VENTRICULAR COLLAPSE
- ┌─────────────────────────────────────────────────────────────────────────────┐
- │ Acute Pulmonary Arterial Obstruction ──► Abrupt Surge in PVR & RV Afterload │
- └──────────────────────────────────────┬──────────────────────────────────────┘
- │
- ▼
- ┌─────────────────────────────────────────────────────────────────────────────┐
- │ Acute RV Dilation & Myocardial Wall Tension ──► RV Ischemia & Decreased RV EF│
- └──────────────────────────────────────┬──────────────────────────────────────┘
- │
- ▼
- ┌─────────────────────────────────────────────────────────────────────────────┐
- │ Interventricular Septal Flattening / Shift ──► Impaired Left Ventricular EDV│
- └──────────────────────────────────────┬──────────────────────────────────────┘
- │
- ▼
- ┌─────────────────────────────────────────────────────────────────────────────┐
- │ Precipitous Drop in Systemic Cardiac Output ──► Hypotension & Cardiogenic Shock│
- │ (Decreased Aortic Root Perfusion ──► Worsens Right Coronary Artery Ischemia) │
- └─────────────────────────────────────────────────────────────────────────────┘
As the dilated right ventricle shifts the interventricular septum toward the left (septal flattening or "D-shaped" left ventricle on echocardiography), left ventricular end-diastolic volume (preload) is severely compromised. This leads to a precipitous drop in systemic cardiac output, systemic hypotension, decreased coronary artery perfusion pressure, worsening RV ischemia, and fatal obstructive shock.
Risk Stratification Framework: ESC Tiers and the 2026 AHA/ACC Categories
Modern emergency management of acute PE is dictated not by anatomical clot burden, but by clinical risk stratification of early mortality. The European Society of Cardiology (ESC) tiers below remain the most widely taught.
In February 2026 the AHA and ACC, with eight other societies, published their first dedicated acute PE guideline (Creager et al.). It introduces AHA/ACC Acute PE Clinical Categories A through E , with subcategories:
- Category Meaning Usual setting
- A Asymptomatic PE (for example, found incidentally) Can be discharged from the ED
- B Symptomatic, low clinical severity score Early discharge generally recommended
- C Elevated severity score with elevated biomarkers and/or RV dysfunction Hospitalize
- D Incipient cardiopulmonary failure Hospitalize; advanced therapy can be considered (D1–D2)
- E Cardiopulmonary failure with persistent hypotension Hospitalize; advanced therapy reasonable (E1)
The 2026 guideline also recommends PE response teams , LMWH over UFH when initial parenteral anticoagulation is needed, DOACs over vitamin K antagonists for patients eligible for oral therapy, and extended anticoagulation after a first unprovoked PE or with a persistent risk factor. Systemic thrombolysis remains recommended for high-risk PE. For Categories E1–2 with acceptable bleeding risk, thrombolysis plus anticoagulation is reasonable over anticoagulation alone, and it may be considered for D1–2.
Clinical Risk Category Hemodynamic Status RV Dysfunction (Echo / CT) Myocardial Injury (Troponin / BNP) 30-Day Mortality Primary Emergency Reperfusion Strategy
High-Risk (Massive PE) Hypotensive / Shock : SBP <90 mmHg for >15 min; Vasopressor required; Cardiac arrest / PEA Present in >95% (RV/LV ratio ≥1.0, hypokinesis) Elevated high-sensitivity Troponin and/or BNP >15% to 30% Immediate Systemic Thrombolysis or emergent surgical/catheter thrombectomy + IV UFH
Intermediate-High Risk (Submassive) Normotensive (SBP ≥90 mmHg) with PESI Class III–V or sPESI ≥1 Present : Echo RV dilation/hypokinesis OR CT RV/LV ratio ≥0.9 Elevated : Positive cardiac Troponin I/T AND elevated BNP/NT-proBNP 3% to 8% Immediate Parenteral Anticoagulation (UFH or LMWH) + ICU/step-down monitoring + Rescue Thrombolysis / CDT if deteriorating
Intermediate-Low Risk (Submassive) Normotensive (SBP ≥90 mmHg) with PESI Class III–V or sPESI ≥1 Either RV dysfunction OR elevated cardiac biomarkers, but NOT both Variable 1% to 3% Parenteral Anticoagulation transitioning to oral DOAC; inpatient admission
Low-Risk PE Normotensive ; PESI Class I–II or sPESI = 0 Absent (Normal RV size and function) Negative (Normal troponin and BNP) <1% Oral DOAC Monotherapy (Apixaban or Rivaroxaban); consider early discharge / outpatient care
Clinical Risk Scoring Tools
Simplified Pulmonary Embolism Severity Index (sPESI) : Evaluates 6 variables (1 point each): Age >80 years, history of cancer, chronic cardiopulmonary disease, heart rate ≥110 beats/min, systolic BP <100 mmHg, and arterial oxygen saturation <90%. A score of 0 identifies low-risk patients (30-day mortality 1.0%), whereas a score of ≥1 denotes intermediate-to-high risk (30-day mortality 10.9%).
Systemic Thrombolytic Pharmacotherapy
Systemic thrombolysis accelerates clot dissolution, rapidly lowers pulmonary artery pressure and PVR, reverses RV dilation, and restores systemic cardiac output in patients with acute obstructive shock.
Alteplase Dosing Protocols
Standard Full-Dose Regimen (Hemodynamically Unstable / Massive PE) :
Alteplase (rtPA) : 100 mg IV continuous infusion administered over 2 hours .
Administration Nuance : Usually administered as a 10 mg IV bolus over 1 to 2 minutes followed by 90 mg IV infused over the remainder of the 2 hours.
Accelerated / Emergency Regimen (Cardiac Arrest or Impending Arrest) :
Alteplase : 50 mg IV push administered over 15 minutes (or 0.6 mg/kg up to a maximum of 50 mg).
Cardiac Arrest Context : In PEA cardiac arrest secondary to suspected or confirmed massive PE, administration of a 50 mg IV bolus should be accompanied by prolonged CPR (European Resuscitation Council guidance suggests considering 60 to 90 minutes ) to allow the fibrinolytic agent to circulate, penetrate the occlusive thrombus, and restore pulmonary perfusion.
Tenecteplase (TNK-tPA) Alternative :
Administered as a single weight-based IV bolus over 5 to 10 seconds: <60 kg: 30 mg; 60 to <70 kg: 35 mg; 70 to <80 kg: 40 mg; 80 to <90 kg: 45 mg; ≥90 kg: 50 mg. (Widely utilized in the PEITHO trial).
Thrombolytic Contraindications Matrix
- Absolute Contraindications Relative Contraindications
- Prior history of intracranial hemorrhage (ICH) Age ≥75 years
Known structural cerebral vascular lesion (e.g., AVM, aneurysm) Systolic BP >180 mmHg or Diastolic BP >110 mmHg on presentation
- Known malignant intracranial neoplasm Major surgery within preceding 3 weeks
- Ischemic stroke within preceding 3 months Recent internal bleeding (within 2 to 4 weeks)
- Suspected aortic dissection Prolonged or traumatic CPR (>10 minutes)
- Active bleeding or bleeding diathesis (excluding menses) Non-compressible vascular punctures
- Significant closed head or facial trauma within preceding 3 months Active peptic ulcer disease
Intracranial or intraspinal surgery within preceding 2 months Current use of oral anticoagulants (e.g., warfarin with elevated INR)
(none) Pregnancy or within 1st postpartum week
Warning
In true massive PE with refractory obstructive shock or active cardiac arrest, absolute contraindications become relative in the face of imminent, 100% fatal circulatory collapse.
The Landmark PEITHO Trial & The Intermediate-Risk Dilemma
One of the most heavily tested concepts on the BCEMP examination is the controversial role of systemic thrombolytic therapy in normotensive intermediate-high risk (submassive) PE .
Study Design : The PEITHO (Pulmonary Embolism Thrombolysis) trial randomized 1,006 normotensive patients with intermediate-high risk PE (exhibiting both RV dysfunction on echo/CT and positive troponin I/T) to weight-based single-bolus tenecteplase plus unfractionated heparin versus placebo plus unfractionated heparin.
Primary Composite Outcome : Fibrinolytic therapy significantly reduced the primary composite endpoint of all-cause mortality or hemodynamic collapse within 7 days ( 2.6% vs 5.6%; p = 0.02 ).
The Critical Caveat : This benefit was driven entirely by a reduction in hemodynamic collapse (1.6% vs 5.0%). There was no statistically significant difference in 30-day all-cause mortality (2.4% vs 3.2%; p = 0.42) .
Hemorrhagic Harm : Systemic fibrinolysis resulted in a dramatic, catastrophic increase in major extracranial bleeding ( 6.3% vs 1.2%; p <0.001 ) and hemorrhagic stroke / intracranial hemorrhage ( 2.0% vs 0.2%; p = 0.003 ), predominantly in patients aged >75 years.
Guideline Consensus : Routine systemic thrombolytic therapy is NOT recommended for intermediate-risk PE . Instead, intermediate-high risk patients should receive therapeutic parenteral anticoagulation and be admitted to an ICU or step-down unit with close monitoring. Full-dose or half-dose "rescue" thrombolysis is initiated only if the patient develops overt hemodynamic decompensation (SBP <90 mmHg, signs of shock).
Advanced Interventional Therapies: CDT & Mechanical Thrombectomy
When systemic thrombolysis carries prohibitive bleeding risk or fails to restore hemodynamics, catheter-based interventional therapies offer targeted pulmonary reperfusion. PULMONARY REPERFUSION MODALITIES
- ┌───────────────────────────────────────────────────────────────────────────┐
- │ Systemic Thrombolysis: Alteplase 100 mg IV over 2h (Rapid, High Bleed Risk)│
- ├───────────────────────────────────────────────────────────────────────────┤
- │ Catheter-Directed Thrombolysis (CDT): Ultrasound-assisted (EKOS) or pigtail│
- │ • Low-dose Alteplase: 0.5–1.0 mg/h per catheter over 12–24h (Max 24 mg) │
- │ • Dramatically reduces major bleeding (ICH <0.5%) vs systemic lytics │
- ├───────────────────────────────────────────────────────────────────────────┤
- │ Percutaneous Mechanical Thrombectomy: Large-bore aspiration (FlowTriever) │
- │ • Rapid mechanical clot extraction without any thrombolytic drug exposure │
- │ • Drug of choice when thrombolytics are absolutely contraindicated │
- ├───────────────────────────────────────────────────────────────────────────┤
- │ Surgical Pulmonary Embolectomy: Cardiopulmonary bypass clot extraction │
- │ • Indicated for massive PE with failed lysis, thrombus-in-transit, or PFO│
- └───────────────────────────────────────────────────────────────────────────┘
- Catheter-Directed Thrombolysis (CDT)
Technique : Infusion catheters (e.g., standard multi-sidehole or ultrasound-accelerated EKOS catheters) are positioned directly into the pulmonary arterial thrombus via femoral or internal jugular access.
Pharmacotherapy : Ultra-low-dose alteplase infused at 0.5 to 1.0 mg/hour per catheter (typically 1.0 mg/h for unilateral PE, or 0.5 mg/h per catheter for bilateral PE) over 12 to 24 hours. Total delivered alteplase dose ranges from 12 to 24 mg (compared to 100 mg for systemic lysis).
Safety Profile : Clinical trials (ULTIMA, SEATTLE II) demonstrated significant reductions in RV/LV diameter ratios and pulmonary artery pressures with an intracranial hemorrhage rate of <0.5%.
Percutaneous Mechanical Thrombectomy
Devices : Large-bore aspiration systems (e.g., Inari FlowTriever, Penumbra Indigo CAT8/Lightning).
Clinical Utility : Enables rapid clot extraction without administering any thrombolytic drug. It is the premier reperfusion strategy for patients with massive or deteriorating intermediate-high risk PE who harbor absolute contraindications to fibrinolytic therapy (e.g., recent intracranial hemorrhage, major surgery within 3 weeks).
Parenteral Anticoagulation Protocols
Parenteral anticoagulation must be initiated immediately upon suspicion or confirmation of acute PE to halt thrombus propagation and prevent secondary thromboembolism.
Unfractionated Heparin (UFH)
Role in High-Risk PE : The 2026 AHA/ACC guideline prefers LMWH over UFH for most patients needing initial parenteral anticoagulation. UFH is still chosen when thrombolysis or a procedure is imminent, in hemodynamically unstable patients, and in severe renal impairment (CrCl <30 mL/min), because it is short-acting and fully reversible.
Pharmacological Advantages : Short half-life (60 to 90 minutes), reticuloendothelial clearance independent of renal excretion, and complete, instantaneous reversibility with protamine sulfate (1 mg per 100 units of heparin administered in the preceding 2 hours, maximum 50 mg).
Weight-Based Dosing Protocol :
IV Bolus : 80 units/kg IV (maximum 10,000 units).
Initial Infusion : 18 units/kg/hour (maximum 2,000 units/hour).
Therapeutic Monitoring : Titrated to institutional anti-Xa levels ( 0.3 to 0.7 IU/mL ) or activated partial thromboplastin time (aPTT 1.5 to 2.5 times control , typically 60 to 80 seconds) measured every 6 hours until stable.
Management During Systemic Thrombolysis :
When initiating systemic alteplase (100 mg over 2 hours), the UFH infusion is generally held during the 2-hour thrombolytic infusion to minimize catastrophic bleeding risk, or infused without an initial bolus.
Following completion of alteplase, UFH should be resumed without a bolus once the aPTT falls below 2 times normal control (<80 seconds).
Low-Molecular-Weight Heparin (Enoxaparin)
Dosing : 1 mg/kg SC every 12 hours or 1.5 mg/kg SC once daily .
Renal Adjustment : If CrCl <30 mL/min, reduce dosing to 1 mg/kg SC once every 24 hours (or preferably switch to UFH due to unpredictable accumulation of anti-Xa activity and heightened bleeding).
Monitoring : Routine anti-Xa monitoring is unnecessary; in extreme obesity (>140 kg or BMI >40 kg/m²), peak anti-Xa measured 4 hours post-dose (target 0.6 to 1.0 IU/mL for q12h dosing) ensures therapeutic adequacy.
Fondaparinux
Mechanism : Synthetic pentasaccharide that selectively binds antithrombin III to inhibit factor Xa.
Weight-Tiered Dosing :
Body weight <50 kg: 5 mg SC once daily .
Body weight 50 to 100 kg: 7.5 mg SC once daily .
Body weight >100 kg: 10 mg SC once daily .
Contraindications : Absolutely contraindicated if CrCl <30 mL/min due to 100% renal elimination and lack of a specific reversal agent.
Transition to Oral DOACs & Special Populations
Direct oral anticoagulants (DOACs) are recommended over vitamin K antagonists (warfarin) for the initial and long-term treatment of VTE in eligible patients due to superior safety, lower intracranial bleeding rates, and operational ease. ORAL DOAC INITIATION REGIMENS
- ┌───────────────────────────────────────────────────────────────────────────┐
- │ SINGLE-DRUG ORAL REGIMENS (NO PARENTERAL LEAD-IN REQUIRED) │
- │ • Apixaban: 10 mg PO BID for 7 days ──► 5 mg PO BID maintenance │
- │ • Rivaroxaban: 15 mg PO BID with food for 21 days ──► 20 mg PO daily food│
- ├───────────────────────────────────────────────────────────────────────────┤
- │ PARENTERAL LEAD-IN REQUIRED (MINIMUM 5–10 DAYS PARENTERAL HEPARIN/LMWH) │
- │ • Dabigatran: 150 mg PO BID (after 5–10 days parenteral anticoagulation) │
- │ • Edoxaban: 60 mg PO daily (after 5–10 days parenteral anticoagulation) │
- │ (Reduce Edoxaban to 30 mg daily if CrCl 15–50 mL/min or weight ≤60 kg) │
- └───────────────────────────────────────────────────────────────────────────┘
- Special Clinical Populations & Nuances
Antiphospholipid Syndrome (APS) : In patients with confirmed triple-positive APS (positive lupus anticoagulant, anticardiolipin, and anti-beta-2-glycoprotein I antibodies), DOACs are strictly contraindicated. The landmark TRAPS trial demonstrated an unacceptably high rate of recurrent arterial thromboembolic events with rivaroxaban compared to warfarin. Patients must receive parenteral heparin bridging to warfarin targeting an INR of 2.0 to 3.0 .
Extreme Obesity (BMI ≥40 kg/m² or Weight >120 kg) : Guidance from the International Society on Thrombosis and Haemostasis (ISTH) endorses standard-dose apixaban or rivaroxaban as appropriate options. For patients with BMI >50 kg/m² or those who have undergone malabsorptive bariatric surgery, LMWH or warfarin remains preferred, or peak and trough anti-Xa drug levels should be evaluated.
Cancer-Associated Thrombosis (CAT) : Oral factor Xa inhibitors (apixaban, edoxaban, rivaroxaban) or LMWH are recommended. In patients with active gastrointestinal or genitourinary mucosal malignancies, apixaban or LMWH is preferred over rivaroxaban/edoxaban due to lower mucosal bleeding rates.
Pregnancy : DOACs cross the placenta and are strictly contraindicated. Warfarin is teratogenic (causing fetal warfarin embryopathy). Therapeutic weight-adjusted LMWH is the drug of choice throughout pregnancy and the immediate postpartum period.